Long-Term Data on QNEXA to be Presented at The American College of Cardiology Annual Meeting

Update: Qsymia (phentermine/topiramate) Now FDA Approved - July 17, 2012

Patients on QNEXA® Had Reduction in Cardiovascular Risk Factors Associated with Sustained Weight Loss Over Two Years

MOUNTAIN VIEW, Calif., March 31, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that data on QNEXA®, its investigational drug candidate, will be featured in a poster presentation at the 60th Annual Scientific Meeting of The American College of Cardiology, being held April 2-5, 2011 in New Orleans, Louisiana.

Following are details about the poster presentation:

The poster will be presented in Hall F of The Ernest N. Morial Convention Center in New Orleans, Louisiana on Sunday, April 3, 2011, 1:45 PM to 4:45 PM (Session 1048)

The Presenter, Dr. Michael H. Davidson, will be at the poster from 3:30 PM to 4:45 PM.

Presenter:

Michael Davidson, MD, FACC, FACP, FNLA

 

Authors:

Davidson, Bowden, Day

 

Title:

Weight Loss and Cardiovascular Risk Reduction Over Two Years with Controlled-Release Phentermine-Topiramate (Presentation Number 1048-293)

 
   


 

About QNEXA Controlled Release Capsules

QNEXA [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking QNEXA have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

About VIVUS

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. QNEXA® is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com

CONTACT:  


 

 
 

 

 

 
 

VIVUS, Inc.

Investor Relations:

The Trout Group

 

Timothy E. Morris


 

Brian Korb

 

Chief Financial Officer


 

646-378-2923

 

650-934-5200


 

 
 
     


 

 

SOURCE VIVUS, Inc.

Posted: April 2011

View comments

Hide
(web4)